Phase II Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia

Trial Profile

Phase II Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Inotuzumab ozogamicin (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jul 2017 Planned End Date changed from 1 Jun 2023 to 1 Sep 2023.
    • 13 Jul 2017 Planned primary completion date changed from 1 Jun 2023 to 1 Sep 2023.
    • 13 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top